Key result
Diabetes mellitus causes pulmonary microvascular damage and reduced lung function, which may increase vulnerability to respiratory infections such as COVID-19.
Why the study?
Pulmonary involvement in diabetes causes underdiagnosed damage and has drawn increased attention during the COVID-19 pandemic due to worse prognoses in patients with diabetes.
Diabetes mellitus contributes to pulmonary vascular and parenchymal damage, emphasizing the importance of glycemic control to prevent lung-related complications.
Answers are grounded in this paper and cite their sources.
May warrant pulmonary monitoring in diabetes; leaves open whether glycemic control mitigates infection risk.
Diabetes mellitus is a chronic disease characterized by hyperglycemia causing damage to the vascular system. The lungs with a large vascular network are also predisposed to diabetes’ vascular damage. Diabetes may lead to pulmonary parenchymal damage besides alterations in the vascular system and the alveolar-capillary membrane. Symptoms and damage caused by diabetes are usually underdiagnosed because of the large pulmonary reserves. Pulmonary involvement in diabetes is an area that draws attention in recent years. This attention increases especially with the new Coronavirus disease-2019 (COVID-19) pandemic when the worse prognosis is detected in diabetics. In this review, possible mechanisms leading to pulmonary involvement and pulmonary function abnormalities in diabetes, the interaction between COVID-19 and diabetes concerning lungs, and the basic effects of antidiabetic drugs on the lungs are discussed in the view of the literature.
No takes yet. Share an insight, caveat, or question.
Canan Ersoy (2020) conducted a review in Diabetes mellitus and pulmonary involvement. Diabetes mellitus causes pulmonary microvascular damage and reduced lung function, which may increase vulnerability to respiratory infections such as COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: